RECURRENT LUNG SMALL CELL CARCINOMA
Clinical trials for RECURRENT LUNG SMALL CELL CARCINOMA explained in plain language.
Never miss a new study
Get alerted when new RECURRENT LUNG SMALL CELL CARCINOMA trials appear
Sign up with your email to follow new studies for RECURRENT LUNG SMALL CELL CARCINOMA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
Genom att skicka in godkänner du våra Användarvillkor
-
Could a DNA-Repair blocker boost chemo in tough lung cancer?
Disease control OngoingThis study tests whether adding the experimental drug berzosertib to standard chemotherapy (topotecan) helps people with small cell lung cancer that has returned after initial treatment. About 104 participants will receive either the combo or topotecan alone. The goal is to see i…
Matched conditions: RECURRENT LUNG SMALL CELL CARCINOMA
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated May 26, 2026 11:23 UTC
-
Triple-Drug attack aims to shrink returned lung cancer
Disease control OngoingThis early-phase trial tests a three-drug combination for small cell lung cancer that has come back after treatment. The drugs include a targeted therapy (tazemetostat), a chemotherapy (topotecan), and an immunotherapy (pembrolizumab). The goal is to find the safest dose and see …
Matched conditions: RECURRENT LUNG SMALL CELL CARCINOMA
Phase: PHASE1 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated May 26, 2026 11:07 UTC
-
Could a PARP inhibitor boost chemo for tough lung cancer?
Disease control OngoingThis study tests whether adding veliparib (a PARP inhibitor) to the chemotherapy drug temozolomide helps people with small cell lung cancer that has come back or stopped responding to treatment. About 97 participants will receive either the combo or a placebo plus temozolomide. T…
Matched conditions: RECURRENT LUNG SMALL CELL CARCINOMA
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated May 15, 2026 11:56 UTC
-
New combo therapy shows promise for HIV patients with advanced cancer
Disease control OngoingThis early-phase trial is testing the safety of combining two cancer drugs—nivolumab and cabozantinib—in people with HIV who have advanced solid tumors. The study includes 8 participants with various cancers that have spread. The goal is to see if the combination can shrink or st…
Matched conditions: RECURRENT LUNG SMALL CELL CARCINOMA
Phase: PHASE1 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated May 11, 2026 20:38 UTC